Public Health: Ustar commit to reach everywhere in need
Empowering Public Health with Accurate Diagnostic Solutions: USTAR’s Response to Infectious Disease Outbreaks
- In an era where global health threats emerge at an unprecedented pace, timely and accurate diagnosis is the cornerstone of epidemic control and public safety. Over more than 2 decades’ devotion to innovative molecular point-of-care (POC) technologies, USTAR offers a comprehensive portfolio of diagnostic platforms designed to meet the diverse needs of infectious disease screening and outbreak response, that empower healthcare providers with rapid, reliable, and actionable results—anytime, anywhere.
Prepared for a comprehensive portfolio of Tuberculosis Diagnostics
- Tuberculosis (TB) is a serious infectious disease caused by Mycobacterium tuberculosis, primarily affecting the lungs but capable of involving other organs. Despite being preventable and curable, TB remains one of the top 10 causes of death worldwide, with an estimated 10.6 million new cases and 1.3 million deaths in 2022, according to WHO.
- In response to the challenges, USTAR has launched EasyNAT TB since 2014, which marks a great improvement for testing TB with a rapid molecular diagnostics, while the turnaround time is only 60 minutes. In 2023, USTAR MultNAT MTC/RIF Assay, released in 2023, has been selected by the Foundation for Innovative New Diagnostics (FIND), due to its advantages of simple operation and cost effectiveness, which is ideal for large-scale screening for areas with limited budget.
- Furthermore, to address the differentiation between TB and Non-tuberculosis bacterium Complex(NTM) and the increasing problem of extensively drug-resistant TB, MultNAT NTM and INH/FLQ are developed and applied for the detection of multiple gene mutations from a single sample. Through the collaboration with FIND and Stop TB partnership, USTAR TB solutions have been widely evaluated in several countries, including South Africa, Cameroon, Uganda, Indonesia, the Philippines and etc.
Continuous responses to on-going threats to Public Health: an innovative solution for Malaria, Monkeypox and Dengue/Zika/Chikungunya
- The dedication to make molecular diagnostic more accessible and equitable for each who are under threats of public health challenges has never stopped. The EasyNAT Malaria assay has been released since 2022 and evaluated at Dicoon Laboratory in the Netherlands, which concludes that EasyNAT Malaria assay show high sensitivity and specificity for malaria screening in the Dutch non-endemic setting.
- Simultaneously, EasyNAT Monkeypox Virus Assay and PortNAT Monkeypox assay has been certified with World Health Organization (WHO) Emergency Use List (EUL) on May of 2025. which are the first point-of-care molecular tests with WHO EUL in China and the 5th in the world. Since June 2025, EasyNAT Monkeypox Assay has been widely deployed in Africa for national screening programs.
- Since the start of 2025, over 3 million suspected dengue cases and approximately 220,000 chikungunya cases are reported. To deal with the outbreaks, USTAR has started to provide MultNAT Dengue/Zika/Chikungunya Assay to support healthcare providers differentiate the threee virus, which usually turns out to be similar symptoms. Furthermore, MultNAT Dengue Genotyping Assay has been developed for differentiate I-IV types, which is critical for outbreak control, predicting disease severity and optimizing vaccine strategies
Looking Ahead: Our Mission for Global Health
- At USTAR, our mission—”Molecular Testing, Anywhere”—drives us to continuously develop affordable, innovative diagnostic solutions that serve people everywhere. From global pandemics to local epidemics, we stand ready to equip healthcare providers with the tools they need to protect lives and public health.
Extensive Test Menu
USTAR Molecular POC Application in Public Health Management
Tuberculosis Test
TB/NTM Test
TB/Drug Resistance
Malaria
Dengue/Zika/Chikungunya
Tropical Fever
HIV
Cholera
Diarrheal Diseases
